Mount Sinai spinout leverages machine learning in fertility tool

A novel approach designed to enable women to accurately measure and monitor key fertility hormones through daily urine samples is being piloted as an at-home, consumer diagnostic tool. OOVA, a Mount Sinai Health System spinout, is partnering with nutritional supplement vendor Thorne Research to make OOVA's fertility monitoring tool available to more than 3 million potential customers and 35,000 clinicians through bundled sales with Thorne's supplements. The company plans to launch in the third quarter of 2019. "[OOVA] is empowering patients to take control over their own fertility. This product combines technological innovation and human behavior to meet an unmet demand in the market," says Alan Copperman, MD, director of the Division of Reproductive Endocrinology and Infertility, and vice chair of the Department of Obstetrics, Gynecology and Reproductive Science at Mount Sinai.